Javelin Pharmaceuticals, Inc. a developer of novel products for pain management, has announced an agreement to expand its commercial supply relationship with Baxter Healthcare Corporation. The new supply agreement relates to Dyloject(TM), Javelin’s proprietary injectable diclofenac product currently marketed in the United Kingdom and in the second of two pivotal trials in the United States, for acute post-operative pain. The expanded relationship provides additional manufacturing capacity for Dyloject, principally for distribution in the European Union, and builds on the existing manufacturing agreement executed between Javelin and Baxter for the United States. “We are pleased to strengthen our relationship with Baxter. This expanded commercial supply agreement will provide increased capacity for Dyloject in Europe as we grow sales of the product in the U.K. and prepare for the anticipated launch of the product in multiple European countries in the near future.” said Martin Driscoll, Javelin’s Chief Executive Officer. “I am pleased we have completed this multi-year expansion of our Dyloject supply agreement with Baxter, which has the potential to significantly improve Dyloject’s gross margins, as the product’s sales volume increases in the UK and additional approvals are gained across Europe,” stated John Taylor, Vice President of Business Development for Javelin. “Solidifying our supply chain for Dyloject should improve the company’s position in our on-going partnership discussions.”
